Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of allogeneic mesenchymal stem cells (MSV-allo) in lupus nephritis
2022-000243-80Phase 2Active
- Sponsor
- Hospital Universitario Rio Hortega
- Start
- May 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lupus nephritis (LN) and systemic lupus erythematosus (SLE) comparing MSV-allo with Placebo (2 arms). Started May 2022; status: active.
02
Drugs
MSV-allo
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2022-000243-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000243-80.